Pfizer To Merge Off-Patent Business With Mylan

29 Jul 2019

Pfizer has announced plans to merge its off-patent unit with Mylan, creating a new generics and biosimilars giant in the US.

Pfizer will merge its Upjohn off-patent unit with Mylan to create a new US-based generics and biosimilars giant, the two companies have confirmed.

Following a flurry of industry rumors, the firms announced on 29 July that they had signed a definitive agreement to combine Mylan with Upjohn

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

08 May 2025

• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

07 May 2025

• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry